Zhao Jiaojiao, Pan Yuchen, Li Xiujun, Zhang Xuefang, Xue Yaxian, Wang Tingting, Zhao Shuli, Hou Yayi
The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China.
Department of Obstetrics and Gynecology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Cell Physiol Biochem. 2017;43(2):589-601. doi: 10.1159/000480531. Epub 2017 Sep 21.
BACKGROUND/AIM: Women with advanced ovarian carcinoma are less likely to receive platinum-based chemotherapy and surgery due to a greater risk of cytotoxicity and poorer outcomes. We attempted to improve a promising therapy against ovarian cancer by using a combination of dihydroartemisinin (DHA) and curcumin (Cur).
Human ovarian cancer SKOV3 cells were treated with DHA, Cur alone, or a combination of both. The viability of SKOV3 cells was measured by Cell Counting Kit-8 (CCK-8) and a colony formation assay. The cell cycle and apoptosis of SKOV3 cells were monitored by flow cytometry. The mRNA and protein expression levels of target genes were respectively examined by qRT-PCR and western blot. The biological effects of miR-124 on midkine (MK) were verified by a luciferase activity analysis.
Combined treatment of DHA and Cur synergistically decreased cell viability, arrested cell cycle, and promoted apoptosis in SKOV3 cells. Moreover, it significantly attenuated the expression of oncogene MK and synergistically upregulated the expression of miR-124. Furthermore, miR-124 was verified to bind directly to the 3'-untranslated region of MK mRNA, resulting in mRNA degradation and reduced MK protein levels. The combination of DHA with Cur significantly inhibited tumor growth in xenograft nude mice without obvious toxicity.
Co-treatment with DHA and Cur exhibited a synergistic anti-tumor effect on SKOV3 cells both in vitro and in vivo.
背景/目的:晚期卵巢癌女性因细胞毒性风险更高且预后较差,接受铂类化疗和手术的可能性较小。我们试图通过联合使用双氢青蒿素(DHA)和姜黄素(Cur)来改进一种有前景的卵巢癌治疗方法。
用人卵巢癌SKOV3细胞分别单独用DHA、Cur处理,或两者联合处理。通过细胞计数试剂盒-8(CCK-8)和集落形成试验检测SKOV3细胞的活力。通过流式细胞术监测SKOV3细胞的细胞周期和凋亡。分别通过qRT-PCR和蛋白质印迹法检测靶基因的mRNA和蛋白质表达水平。通过荧光素酶活性分析验证miR-124对中期因子(MK)的生物学作用。
DHA和Cur联合处理协同降低了SKOV3细胞的活力,使细胞周期停滞,并促进其凋亡。此外,它显著减弱了癌基因MK的表达,并协同上调了miR-124的表达。此外,已证实miR-124直接与MK mRNA的3'非翻译区结合,导致mRNA降解并降低MK蛋白水平。DHA与Cur的组合显著抑制了异种移植裸鼠的肿瘤生长,且无明显毒性。
DHA和Cur联合处理在体外和体内对SKOV3细胞均表现出协同抗肿瘤作用。